116 results
Page 3 of 6
8-K
EX-1.1
dj7neja5ira46w
19 Jul 21
Entry into a Material Definitive Agreement
4:15pm
424B5
c2redi6
16 Jul 21
Prospectus supplement for primary offering
9:35am
424B5
7j6tk
14 Jul 21
Prospectus supplement for primary offering
5:19pm
8-K
EX-10.3
2zw83lfqltj2bhedyqef
14 Jun 21
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
voxrj 2uv
6 May 21
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
8:16am
8-K
EX-99.1
fao1 4cizxb
26 Feb 21
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
6:53am
8-K
EX-99.1
8ko459yf 5sa5g
18 Feb 21
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
7:40am
8-K
EX-10.1
ztrcu61klqnse
4 Jan 21
Entry into a Material Definitive Agreement
6:03am
8-K
EX-99.1
myx wniv6
5 Nov 20
Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
9qxw8qjiyv 75iz5
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
8-K
EX-10.1
udobdz y33pegy
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
8-K
EX-99.1
ops1n j0zonztb7m
11 Sep 20
Regulation FD Disclosure
8:01am
8-K
EX-1.1
ccgd8x6bme
10 Aug 20
Entry into a Material Definitive Agreement
12:00am